US-based medical technology company Verge Medical has acquired the RoVo System from 2MG Medical to enhance its offerings in peripheral embolic protection.
The acquisition strengthens Verge’s solutions for coronary and peripheral vascular interventions, improving safety and efficiency in treating Peripheral Vascular Disease (PVD).
The RoVo System is designed to work alongside standard PVD treatments, such as atherectomies, balloons, and stents, to remove distal emboli formed during procedures.
Distal embolization is a serious complication in peripheral interventions like atherectomy.
The System utilises 2MG Medical’s Temporary Occlusion Embolectomy (TOE) technique to prevent ‘downstream’ flow of emboli, ensuring safer outcomes.
The TOE technique temporarily blocks the downstream blood flow using compression, and a vacuum-activated catheter creates a vortex effect to effectively capture and remove debris.
The acquisition of the RoVo System expands Verge Medical’s portfolio, which includes the FLASH Aorto-Ostial Angioplasty System and the Wavella specialty infusion catheter.
Approved by the US Food and Drug Administration (FDA), the RoVo system will support Verge’s goal of advancing vascular care through physician-driven solutions.
Verge Medical CEO Mike Buck said: “The RoVo System exemplifies Verge Medical’s mission to provide targeted solutions that are aligned with today’s clinical, workflow and reimbursement realities.
“RoVo is a smart, accessible technology designed to empower physicians to manage distal embolization with greater confidence.
“We look forward delivering innovative, practical tools like RoVo into the hands of physicians who need them most.”
In March 2025, Ostial Corp., a company focused on aorto-ostial interventions, acquired the Wavella technology from Crossfire Medical and rebranded as Verge Medical.
The strategic move expands Verge’s presence in the coronary and peripheral markets, offering products for both inpatient and office-based settings.
